Supply Chain/Logistics

Jul 30, 2012
By BioPharm International Editors
A report from the European Commission shows that fake pharmaceuticals were the top articles detained by European-Union customs in 2011.
Jun 11, 2012
European and US associations call for continued vigilance against the threat of counterfeit medicines.
Jun 01, 2012
BioPharm International
The contract provider needs to know as much as the NDA holder.
May 03, 2012
By BioPharm International Editors
The UK's Medicines and Healthcare products Regulatory Agency has launched a new anticounterfeiting strategy with the aim of curbing the occurrence of falsified medicines in the county's supply chain.
May 01, 2012
BioPharm International
No matter the time or cost, knowing what's going on inside your facilities is always going to be worth the effort.
Nov 22, 2011
BioPharm International
By BioPharm International Editors
The EMA released a concept paper for consultation on Nov. 8, 2011, that recommends a revision to Annex 16 of the Guide to Good Manufacturing of Medicinal Products to address more complicated global supply chains and new falsified medicines legislation. Since Annex 16 was introduced in 2001, a number of positive and negative trends have occurred in the pharmaceutical industry. In particular, confusion has arisen over the role of the qualified person (QP), and harmonization of requirements has been lost between member states. The EMA cites several commonly asked questions within the concept paper:
Jul 01, 2011
BioPharm International
Incorporating regulatory requirements into the product life cycle is crucial.
May 01, 2011
BioPharm International
Addressing supply-chain challenges.
Apr 12, 2011
BioPharm International
Nigeria Looks to Simple Packaging Controls and International Cooperation to Curb Counterfeit Drugs
Jun 18, 2010
Vetter held a groundbreaking ceremony for its new facility in Ravensburg.
native1_300x100
lorem ipsum